Melanoma Institute part of $14m melanoma project grant
25 March 2015
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
The research, funded as part of the National Health and Medical Research Council (NHMRC) Program scheme, will commence in 2016 and will be administered through Macquarie University in Sydney. The team’s investigators are largely based at the University of Sydney, as well as the Centenary Institute, the Westmead Millennium Institute for Medical Research, and the QIMR Berghofer Medical Research Institute.
All investigators are part of MIA, the world’s largest cancer centre dedicated to research and treatment of melanoma, and have been linked as a NHMRC Program since 2006. Treating 1900 new melanoma patients annually, the MIA’s repository of clinical research data and melanoma biospecimens is the largest in the world.
Lead researcher Professor Rick Kefford from MIA and Macquarie University said the project had real prospects of accelerating prevention and early detection of melanoma.
“In this era of rapid change the program could make realistic progress towards a cure of metastatic disease,” Professor Kefford said.
MIA tumour samples and data from people receiving targeted and immune treatments for melanoma are driving these promising advances. The Program has also recruited thousands of people from the community, and families with a strong history of melanoma, to lead discovery of melanoma risk genes.
“In the last few years our program has helped drive large-scale genomic analysis of melanoma, and this will continue to be a cornerstone of our research,” says Professor Graham Mann of MIA, Westmead Millennium Institute and the University of Sydney. “These approaches have already been highly successful, and we have great hopes for better prevention, detection and treatment of melanoma in the future,” he said.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.